The Experts below are selected from a list of 135 Experts worldwide ranked by ideXlab platform

Nigel Curtis - One of the best experts on this subject based on the ideXlab platform.

  • the immunomodulatory effects of measles mumps rubella vaccination on persistence of Heterologous Vaccine responses
    Immunology and Cell Biology, 2019
    Co-Authors: Petra Zimmermann, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Nigel Curtis
    Abstract:

    It is proposed that measles-containing Vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to Heterologous Vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) Vaccine on the persistence of antibodies to a broad range of Heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) Vaccines while the remaining 99 children had not yet received these Vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these Vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naive participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other Vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to Heterologous Vaccines received in the first year of life.

  • The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on Heterologous Vaccine responses in infants
    Vaccine, 2019
    Co-Authors: Petra Zimmermann, Mihai G. Netea, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Susan Donath, Nicole L. Messina, Nicole Ritz, Katie L Flanagan, Nigel Curtis
    Abstract:

    Abstract Introduction Bacillus Calmette-Guerin Vaccine (BCG), one of the most widely used Vaccines, does not only provide protection against tuberculosis and other mycobacterial infections, but also has non-specific (Heterologous) immunomodulatory effects. In participants in a randomised trial, we investigated the effect of neonatal BCG immunisation on antibody responses to routine infant Vaccines given in the first year of life. Methods Antibodies against antigens in the diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib), and the 13-valent pneumococcal conjugate Vaccines were measured in 91 (45 BCG-vaccinated, 46 BCG-naive) infants one month after, and in 310 (169 BCG-vaccinated, 141 BCG-naive) infants seven months after immunisation at 6 weeks, 4 and 6 months of age. In addition, antibodies against meningococcus C, Hib, measles, mumps, and rubella were measured in 147 (78 BCG-vaccinated, 69 BCG-naive) infants one month after immunisation at 12 months of age. The seroprotection rates for each Vaccine and the geometric mean concentrations (GMC) of antibodies were compared in BCG-vaccinated and BCG-naive infants. Results At 7 months of age, seroprotection rates were high in both BCG-vaccinated and BCG-naive infants. At 13 months of age, seroprotection rates were lower than at 7 months of age, particularly for pertussis and a number of pneumococcal antigens, with generally higher rates for the latter in BCG-vaccinated infants. Although not statistically significant, antibody responses in BCG-vaccinated infants were consistently higher against diphtheria, tetanus, and pneumococcal antigens at both 7 and 13 months of age, and against measles and mumps at 13 months of age, but were lower against Hib one month after immunisation at both 7 and 13 months of age. Conclusion The immunomodulatory effect of BCG on antibody responses to Heterologous Vaccines adds to the evidence that BCG immunisation at birth has broad Heterologous effects on the infant immune system.

Petra Zimmermann - One of the best experts on this subject based on the ideXlab platform.

  • the immunomodulatory effects of measles mumps rubella vaccination on persistence of Heterologous Vaccine responses
    Immunology and Cell Biology, 2019
    Co-Authors: Petra Zimmermann, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Nigel Curtis
    Abstract:

    It is proposed that measles-containing Vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to Heterologous Vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) Vaccine on the persistence of antibodies to a broad range of Heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) Vaccines while the remaining 99 children had not yet received these Vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these Vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naive participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other Vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to Heterologous Vaccines received in the first year of life.

  • The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on Heterologous Vaccine responses in infants
    Vaccine, 2019
    Co-Authors: Petra Zimmermann, Mihai G. Netea, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Susan Donath, Nicole L. Messina, Nicole Ritz, Katie L Flanagan, Nigel Curtis
    Abstract:

    Abstract Introduction Bacillus Calmette-Guerin Vaccine (BCG), one of the most widely used Vaccines, does not only provide protection against tuberculosis and other mycobacterial infections, but also has non-specific (Heterologous) immunomodulatory effects. In participants in a randomised trial, we investigated the effect of neonatal BCG immunisation on antibody responses to routine infant Vaccines given in the first year of life. Methods Antibodies against antigens in the diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib), and the 13-valent pneumococcal conjugate Vaccines were measured in 91 (45 BCG-vaccinated, 46 BCG-naive) infants one month after, and in 310 (169 BCG-vaccinated, 141 BCG-naive) infants seven months after immunisation at 6 weeks, 4 and 6 months of age. In addition, antibodies against meningococcus C, Hib, measles, mumps, and rubella were measured in 147 (78 BCG-vaccinated, 69 BCG-naive) infants one month after immunisation at 12 months of age. The seroprotection rates for each Vaccine and the geometric mean concentrations (GMC) of antibodies were compared in BCG-vaccinated and BCG-naive infants. Results At 7 months of age, seroprotection rates were high in both BCG-vaccinated and BCG-naive infants. At 13 months of age, seroprotection rates were lower than at 7 months of age, particularly for pertussis and a number of pneumococcal antigens, with generally higher rates for the latter in BCG-vaccinated infants. Although not statistically significant, antibody responses in BCG-vaccinated infants were consistently higher against diphtheria, tetanus, and pneumococcal antigens at both 7 and 13 months of age, and against measles and mumps at 13 months of age, but were lower against Hib one month after immunisation at both 7 and 13 months of age. Conclusion The immunomodulatory effect of BCG on antibody responses to Heterologous Vaccines adds to the evidence that BCG immunisation at birth has broad Heterologous effects on the infant immune system.

Kirsten P. Perrett - One of the best experts on this subject based on the ideXlab platform.

  • the immunomodulatory effects of measles mumps rubella vaccination on persistence of Heterologous Vaccine responses
    Immunology and Cell Biology, 2019
    Co-Authors: Petra Zimmermann, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Nigel Curtis
    Abstract:

    It is proposed that measles-containing Vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to Heterologous Vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) Vaccine on the persistence of antibodies to a broad range of Heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) Vaccines while the remaining 99 children had not yet received these Vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these Vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naive participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other Vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to Heterologous Vaccines received in the first year of life.

  • The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on Heterologous Vaccine responses in infants
    Vaccine, 2019
    Co-Authors: Petra Zimmermann, Mihai G. Netea, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Susan Donath, Nicole L. Messina, Nicole Ritz, Katie L Flanagan, Nigel Curtis
    Abstract:

    Abstract Introduction Bacillus Calmette-Guerin Vaccine (BCG), one of the most widely used Vaccines, does not only provide protection against tuberculosis and other mycobacterial infections, but also has non-specific (Heterologous) immunomodulatory effects. In participants in a randomised trial, we investigated the effect of neonatal BCG immunisation on antibody responses to routine infant Vaccines given in the first year of life. Methods Antibodies against antigens in the diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib), and the 13-valent pneumococcal conjugate Vaccines were measured in 91 (45 BCG-vaccinated, 46 BCG-naive) infants one month after, and in 310 (169 BCG-vaccinated, 141 BCG-naive) infants seven months after immunisation at 6 weeks, 4 and 6 months of age. In addition, antibodies against meningococcus C, Hib, measles, mumps, and rubella were measured in 147 (78 BCG-vaccinated, 69 BCG-naive) infants one month after immunisation at 12 months of age. The seroprotection rates for each Vaccine and the geometric mean concentrations (GMC) of antibodies were compared in BCG-vaccinated and BCG-naive infants. Results At 7 months of age, seroprotection rates were high in both BCG-vaccinated and BCG-naive infants. At 13 months of age, seroprotection rates were lower than at 7 months of age, particularly for pertussis and a number of pneumococcal antigens, with generally higher rates for the latter in BCG-vaccinated infants. Although not statistically significant, antibody responses in BCG-vaccinated infants were consistently higher against diphtheria, tetanus, and pneumococcal antigens at both 7 and 13 months of age, and against measles and mumps at 13 months of age, but were lower against Hib one month after immunisation at both 7 and 13 months of age. Conclusion The immunomodulatory effect of BCG on antibody responses to Heterologous Vaccines adds to the evidence that BCG immunisation at birth has broad Heterologous effects on the infant immune system.

Fiona R. M. Van Der Klis - One of the best experts on this subject based on the ideXlab platform.

  • the immunomodulatory effects of measles mumps rubella vaccination on persistence of Heterologous Vaccine responses
    Immunology and Cell Biology, 2019
    Co-Authors: Petra Zimmermann, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Nigel Curtis
    Abstract:

    It is proposed that measles-containing Vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to Heterologous Vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) Vaccine on the persistence of antibodies to a broad range of Heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) Vaccines while the remaining 99 children had not yet received these Vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these Vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naive participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other Vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to Heterologous Vaccines received in the first year of life.

  • The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on Heterologous Vaccine responses in infants
    Vaccine, 2019
    Co-Authors: Petra Zimmermann, Mihai G. Netea, Kirsten P. Perrett, Fiona R. M. Van Der Klis, Susan Donath, Nicole L. Messina, Nicole Ritz, Katie L Flanagan, Nigel Curtis
    Abstract:

    Abstract Introduction Bacillus Calmette-Guerin Vaccine (BCG), one of the most widely used Vaccines, does not only provide protection against tuberculosis and other mycobacterial infections, but also has non-specific (Heterologous) immunomodulatory effects. In participants in a randomised trial, we investigated the effect of neonatal BCG immunisation on antibody responses to routine infant Vaccines given in the first year of life. Methods Antibodies against antigens in the diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib), and the 13-valent pneumococcal conjugate Vaccines were measured in 91 (45 BCG-vaccinated, 46 BCG-naive) infants one month after, and in 310 (169 BCG-vaccinated, 141 BCG-naive) infants seven months after immunisation at 6 weeks, 4 and 6 months of age. In addition, antibodies against meningococcus C, Hib, measles, mumps, and rubella were measured in 147 (78 BCG-vaccinated, 69 BCG-naive) infants one month after immunisation at 12 months of age. The seroprotection rates for each Vaccine and the geometric mean concentrations (GMC) of antibodies were compared in BCG-vaccinated and BCG-naive infants. Results At 7 months of age, seroprotection rates were high in both BCG-vaccinated and BCG-naive infants. At 13 months of age, seroprotection rates were lower than at 7 months of age, particularly for pertussis and a number of pneumococcal antigens, with generally higher rates for the latter in BCG-vaccinated infants. Although not statistically significant, antibody responses in BCG-vaccinated infants were consistently higher against diphtheria, tetanus, and pneumococcal antigens at both 7 and 13 months of age, and against measles and mumps at 13 months of age, but were lower against Hib one month after immunisation at both 7 and 13 months of age. Conclusion The immunomodulatory effect of BCG on antibody responses to Heterologous Vaccines adds to the evidence that BCG immunisation at birth has broad Heterologous effects on the infant immune system.

Thomas W Geisbert - One of the best experts on this subject based on the ideXlab platform.

  • Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
    2016
    Co-Authors: Chad E. Mire, Krystle N. Agans, Andrea Marzi, Heinz Feldmann, Joan B Geisbert, Thomas W Geisbert
    Abstract:

    Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed Vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based Vaccine vectors, which encode an EBOV glycoprotein in place of the VSV glycoprotein, have shown 100 % efficacy against homologous Sudan ebolavirus (SEBOV) or Zaire ebolavirus (ZEBOV) challenge in NHPs. In addition, a single injection of a blend of three rVSV vectors completely protected NHPs against challenge with SEBOV, ZEBOV, the former Côte d’Ivoire ebolavirus, and Marburg virus. However, recent studies suggest that complete protection against the newly discovered Bundibugyo ebolavirus (BEBOV) using several different Heterologous filovirus Vaccines is more difficult and presents a new challenge. As BEBOV caused nearly 50 % mortality in a recent outbreak any filovirus Vaccine advanced for human use must be able to protect against this new species. Here, we evaluated several different strategies against BEBOV using rVSV-based Vaccines. Groups of cynomolgus macaques were vaccinated with a single injection of a homologous BEBOV Vaccine, a single injection of a blended Heterologous Vaccine (SEBOV/ZEBOV), or a prime-boost using Heterologous SEBOV and ZEBOV vectors. Animals were challenged with BEBOV 29–36 days after initial vaccination. Macaques vaccinated with the homologous BEBOV Vaccine or the prime-boost showed no overt signs of illness and survived challenge. In contrast, animals vaccinated with the Heterologous blended Vaccine and unvaccinated control animals developed severe clinical symptom

  • Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
    PLoS Neglected Tropical Diseases, 2013
    Co-Authors: Chad E. Mire, Krystle N. Agans, Andrea Marzi, Heinz Feldmann, Joan B Geisbert, Thomas W Geisbert
    Abstract:

    Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed Vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based Vaccine vectors, which encode an EBOV glycoprotein in place of the VSV glycoprotein, have shown 100% efficacy against homologous Sudan ebolavirus (SEBOV) or Zaire ebolavirus (ZEBOV) challenge in NHPs. In addition, a single injection of a blend of three rVSV vectors completely protected NHPs against challenge with SEBOV, ZEBOV, the former Côte d'Ivoire ebolavirus, and Marburg virus. However, recent studies suggest that complete protection against the newly discovered Bundibugyo ebolavirus (BEBOV) using several different Heterologous filovirus Vaccines is more difficult and presents a new challenge. As BEBOV caused nearly 50% mortality in a recent outbreak any filovirus Vaccine advanced for human use must be able to protect against this new species. Here, we evaluated several different strategies against BEBOV using rVSV-based Vaccines. Groups of cynomolgus macaques were vaccinated with a single injection of a homologous BEBOV Vaccine, a single injection of a blended Heterologous Vaccine (SEBOV/ZEBOV), or a prime-boost using Heterologous SEBOV and ZEBOV vectors. Animals were challenged with BEBOV 29-36 days after initial vaccination. Macaques vaccinated with the homologous BEBOV Vaccine or the prime-boost showed no overt signs of illness and survived challenge. In contrast, animals vaccinated with the Heterologous blended Vaccine and unvaccinated control animals developed severe clinical symptoms consistent with BEBOV infection with 2 of 3 animals in each group succumbing. These data show that complete protection against BEBOV will likely require incorporation of BEBOV glycoprotein into the Vaccine or employment of a prime-boost regimen. Fortunately, our results demonstrate that Heterologous rVSV-based filovirus Vaccine vectors employed in the prime-boost approach can provide protection against BEBOV using an abbreviated regimen, which may have utility in outbreak settings.